← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › Proton pump inhibitors
esomeprazole
A02BC05
Forms & Strengths
- Delayed-release capsules: 20 mg, 40 mg
- Delayed-release oral suspension packets: 10 mg, 20 mg, 40 mg
- Intravenous injection/infusion: 20 mg, 40 mg per vial
Adult Dosing
- Gastroesophageal Reflux Disease (GERD): 20 mg to 40 mg orally once daily for 4 to 8 weeks
- H. pylori eradication (triple therapy): 40 mg orally once daily with amoxicillin and clarithromycin
- Risk reduction of NSAID-associated gastric ulcers: 20 mg or 40 mg orally once daily for up to 6 months
- Pathological hypersecretion conditions (e.g., Zollinger-Ellison syndrome): 40 mg orally twice daily, adjusted up to 240 mg daily
Pediatric Dosing
- GERD (Ages 1 month to <1 year): 2.5 mg once daily (1 month to <6 months) or 5 mg to 10 mg once daily (6 months to <1 year)
- GERD (Ages 1 to 11 years): 10 mg to 20 mg once daily for up to 8 weeks
- GERD (Ages 12 to 17 years): 20 mg to 40 mg once daily for up to 8 weeks
Indications
- Treatment of gastroesophageal reflux disease (GERD)
- Healing of erosive esophagitis
- Eradication of Helicobacter pylori to reduce risk of duodenal ulcer recurrence
- Risk reduction of nonsteroidal anti-inflammatory drug (NSAID)-associated gastric ulcers
- Long-term management of pathological hypersecretory conditions including Zollinger-Ellison syndrome
Mechanism of Action
- Proton pump inhibitor (PPI) that covalently binds to H+/K+-ATPase enzyme system
- Inhibits final step of gastric acid secretion in parietal cells
- Suppresses both basal and stimulated gastric acid secretion
Contraindications
- Known hypersensitivity to esomeprazole, substituted benzimidazoles, or any component of the formulation
- Concomitant use with rilpivirine-containing products
Adverse Reactions
- Headache
- Diarrhea
- Nausea
- Flatulence
- Abdominal pain
- Constipation
- Dry mouth
- Rare: Clostridioides difficile-associated diarrhea, hypomagnesemia, vitamin B12 deficiency, bone fractures, acute interstitial nephritis
Drug Interactions
- CYP2C19 and CYP3A4 substrates/inhibitors (e.g., clopidogrel, methotrexate, tacrolimus)
- Drugs dependent on gastric pH for absorption (e.g., ketoconazole, iron salts, digoxin, rilpivirine)
- Increased risk of hypomagnesemia with concurrent diuretics
Curated Content: Needs Vetting Before Put to Clinical Use